Información:
Error:
ID
12935
Descripción
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00005908
Link
https://clinicaltrials.gov/show/NCT00005908
Palabras clave
Versiones (1)
- 6/1/16 6/1/16 -
Subido en
6 de enero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Breast Cancer NCT00005908
Eligibility Breast Cancer NCT00005908
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00005908
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
breast cancer stage
Item
stage ii or iii breast cancer with a tumor size of greater than 2 cm. patients with a previous biopsy are eligible provided adequate tumor tissue remains for biopsy in this study.
boolean
C0678222 (UMLS CUI [1,1])
C0027646 (UMLS CUI [1,2])
C0005558 (UMLS CUI [2])
C0027646 (UMLS CUI [1,2])
C0005558 (UMLS CUI [2])
age
Item
at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Hematopoiesis
Item
adequate hematopoietic function as defined by absolute neutrophil count greater than 1200/mm^3 and platelet count greater than 100,000/mm^3.
boolean
C0200633 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0032181 (UMLS CUI [2])
creatinine
Item
adequate renal function as defined by creatinine less than 1.6 mg/dl.
boolean
C0201976 (UMLS CUI [1])
liver function
Item
adequate hepatic function as defined by total (t.) bilirubin less than 1.4 mg/dl and serum glutamic oxaloacetic transaminase (sgot)/serum glutamic pyruvic transaminase (sgpt) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times upper limit of normal
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
C0201836 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201850 (UMLS CUI [4])
zubrod
Item
zubrod performance status 0-2.
boolean
C1518965 (UMLS CUI [1,1])
C0449820 (UMLS CUI [1,2])
C0449820 (UMLS CUI [1,2])
comorbidity
Item
medical or psychiatric condition that, in the opinion of the principal investigator, would preclude chemotherapy administration. patients may be evaluated by psychiatry or medical subspecialties as appropriate.
boolean
C0009488 (UMLS CUI [1])
pregnancy, lactating
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C2828358 (UMLS CUI [2])
C2828358 (UMLS CUI [2])
bleeding disorders
Item
known bleeding disorders
boolean
C0005779 (UMLS CUI [1])
hypersensitivity
Item
hypersensitivity to tween 80 (polysorbate)
boolean
C0020517 (UMLS CUI [1,1])
C0041417 (UMLS CUI [1,2])
C0041417 (UMLS CUI [1,2])
heart disease
Item
cardiac ejection fraction below normal limits, myocardial infarction within the past 12 months, or symptomatic arrhythmia requiring medical intervention.
boolean
C0018799 (UMLS CUI [1])
chemotherapy, hormone therapy
Item
prior chemotherapy or hormonal therapy for breast cancer. patients treated with hormonal chemoprevention (tamoxifen or raloxifene) will be eligible.
boolean
C0392920 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C0279025 (UMLS CUI [2])
malignancy
Item
active malignancy diagnosed within the last 5 years. (cervical cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible).
boolean
C0006826 (UMLS CUI [1])